This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the p…

Childhood Acute Lymphoblastic LeukemiaChildhood Lymphoblastic Lymphoma

~Estimated

~$10 – $750

Mayo ClinicNCT07221656

Observational

A Randomized Phase II Trial of Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patient…

Acute LeukemiaAcute Lymphoblastic Lymphoma

~Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06803745

Phase 1

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…

Hematologic MalignancyAMLALL+8 more

~Estimated

~$10 – $7,500

Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770

← PreviousPage 4 of 4Next →